Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA
Dates
study started
completion around
Principal Investigator
by April W. Armstrong, MD, MPH (ucla)
Headshot of April W. Armstrong
April W. Armstrong

Description

Summary

This is a study to evaluate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult participants with moderate to severe hidradenitis suppurativa. Participants will be randomized 2:1 to either sonelokimab or matching placebo up to Week 16.

Official Title

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab in Adult Participants with Moderate to Severe Hidradenitis Suppurativa

Keywords

Hidradenitis Suppurativa, Hidradenitis, Sweat Gland Diseases, Skin Diseases, Skin Diseases, Bacterial, Suppuration, Anti-Inflammatory Agents, Sonelokimab, Nanobody, Apocrine Gland Disease

Eligibility

You can join if…

Open to people ages 18 years and up

  1. Participants must be at least 18 years of age at the time of signing the informed consent.
  2. Participants who are diagnosed with hidradenitis suppurativa as determined by the investigator and have a history of signs and symptoms of hidradenitis suppurativa for at least 6 months before signing the informed consent.
  3. Participants who have had an inadequate response to appropriate systemic antibiotics for treatment of hidradenitis suppurativa (or demonstrated intolerance to, or had a contraindication to, systemic antibiotics for treatment of their HS), in the investigator's opinion.
  4. Participants who have a total AN count of ≥5.
  5. Participants who have HS lesions present in ≥2 distinct anatomical areas, at least one of which must contain single or multiple fistulas (ie, be Hurley Stage II or III).

You CAN'T join if...

  1. Participants with a known hypersensitivity to sonelokimab or any of its excipients.
  2. Participants with any other active skin disease or condition that may, in the opinion of the investigator, interfere with the assessment of HS.
  3. Participants with underlying conditions that, in the opinion of the investigator, potentially places the participant at unacceptable risk.
  4. Participants with current severe or uncontrolled disease(s) that put(s) the participant at increased risk in the investigator's opinion, would preclude the participant from adhering to the protocol or completing the study per protocol.
  5. Participants with any other known autoimmune disease or any medical condition that in the opinion of the investigator would interfere with an accurate assessment of clinical symptoms of HS.
  6. Participants with a gastrointestinal condition including inflammatory bowel disease or diagnosis of ulcerative colitis or Crohn's disease.

Locations

  • Clinical Site accepting new patients
    San Diego California 92123 United States
  • Clinical Site accepting new patients
    Northridge California 91325 United States
  • Clinical Site accepting new patients
    Sacramento California 95815 United States

Lead Scientist at University of California Health

  • April W. Armstrong, MD, MPH (ucla)
    Dr. April Armstrong is Professor and Chief of Dermatology at University of California Los Angeles (UCLA). She oversees and leads the dermatology division, including managing clinical operations and promoting research and education. She also serves as Co-Director for Network Resources at the UCLA Clinical and Translational Research Institute.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
MoonLake Immunotherapeutics AG
ID
NCT06411899
Phase
Phase 3 Hidradenitis Suppurativa Research Study
Study Type
Interventional
Participants
Expecting 400 study participants
Last Updated